1 / 51

BLA #125019 ZEVALIN™ Kit

BLA #125019 ZEVALIN™ Kit. Philippe Bishop, MD FDA/CBER September 11, 2001. Presentation Outline. Regulatory History Study Results Efficacy Safety Dosimetry & Biodistribution Summary Committee Questions. BLA #125019 Regulatory History. ZEVALIN ™ BLA Contents.

orlando
Télécharger la présentation

BLA #125019 ZEVALIN™ Kit

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BLA #125019ZEVALIN™ Kit Philippe Bishop, MD FDA/CBER September 11, 2001

  2. Presentation Outline • Regulatory History • Study Results • Efficacy • Safety • Dosimetry & Biodistribution • Summary • Committee Questions

  3. BLA #125019 Regulatory History

  4. ZEVALIN™ BLA Contents Results of 5 clinical studies were submitted in support of the proposed biologic license application

  5. Proposed Indication Treatment of patients with relapsed or refractory low-grade, follicular or CD20+ transformed B-cell NHL, and for the treatment of patients with RITUXAN®-refractory follicular NHL.

  6. Regulatory History Date 11-24-92 IND Submission 6-13-96 106-03 2-24-98 106-04 5-20-98 106-05 7-7-98 106-06 12-9-99 106-98

  7. Regulatory History

  8. Efficacy

  9. ZEVALIN™ Therapy Development 1 major controlled efficacy study AND 1 supportive trial in the refractory setting

  10. Efficacy StudyTrial 106-04 Active control: rituximab Stratification by histology (IWF A/Follicular/Transformed) 1o efficacy endpoint: superior ORR (LEXCOR)

  11. 106-04 Primary Efficacy Analysis #Protocol Defined Response Criteria/LEXCOR Evaluation *Cochran-Mantel-Haenszel test stratified by histology type

  12. 106-04 Subgroup AnalysisORR

  13. 106-04 Duration of Response (DR) *K-M estimated medians (months)

  14. 106-04 Subgroup AnalysisDuration of Response

  15. Supportive StudyTrial 106-06 Non-randomized trial in rituximab-refractory follicular B-cell NHL 1o efficacy endpoint: ORR (LEXCOR)

  16. Trial 106-06 In this patient population an ORR ≥ 35% and a DR comparable to prior rituximab was considered acceptable evidence of activity

  17. 106-06 Primary Efficacy Analysis *Protocol Defined Response Criteria/LEXCOR Evaluation

  18. 106-06 Duration of Response* * Protocol defined analysis # K-M estimated medians (months)

  19. ZEVALIN vs. Prior Rituximab Therapy Analysis DR for ZEVALIN™ therapy compared to the prior rituximab therapy Each subject used as their own control • Favors ZEVALIN™ if duration of response to ZEVALIN™ is at least 1 month longer • Favors rituximab if duration of response to rituximab is at least 1 month longer

  20. 106-06Duration of Response DR for ZEVALIN™ therapy compared to the prior rituximab therapy Each subject used as their own control N % Favors ZEVALIN™ 29 54 Favors Rituximab 5 9 Neither 20 37

  21. EfficacyFDA Assessment • ZEVALIN™ therapy has demonstrable and durable anti-tumor activity (ORR) in follicular subjects. • Limited data in IWF A and transformed subjects preclude definitive conclusions.

  22. Safety

  23. Hematologic ToxicityWithin First 90 Days (N=392)

  24. Grade 3-4 ANCN=214/392 (55%)

  25. Immunologic Effects • All subjects had B-cell depletion • Median time to baseline recovery = 6 months • Transient IgM decline • IgG and IgA remained normal

  26. Infections 114/358 (32%) had a total of 183 events 28/358 (8%) had Grade 3-4 events

  27. Grade 3-4 PLTN=224/392 (57%)

  28. Study 106-05: Grades 3-4 PLTN=26/30 (87%)

  29. Incidence of Bleeding • 62 (18%) subjects had at least 1 bleeding event • 7 subjects had a total of 12 Grade 3-5 events • 2 intracranial bleed  Death • 1 vaginal bleed • 1 ecchymosis • 4 GI bleed • 1 hematemesis • 3 melena 5 subjects

  30. Exploratory Analyses Cytopenias Risk Factors • Baseline BM involvement • Number of prior regimens • Prior fludarabine therapy • Baseline platelet level

  31. Non Cytopenic AEsPer Patient Incidence (N=358)

  32. Common Non-Heme AEsStudy 106-04

  33. Notable AEs (All Grades)Study 106-04

  34. Secondary Malignanciesn=349 • 3 AML • 2 MDS • 1 meningioma Onset 8 to 34 months post ZEVALIN™ therapy and 4 to 13 years following NHL diagnosis

  35. HAMA/HACA Response(N=211) 5 subjects had positive HAMA titers • 2 had positive baseline HAMA titers • 3 developed titers post-treatment 3 subjects had positive HACA titers • 2 had positive baseline HACA titers • 1 developed titers post-treatment

  36. Deaths 70 of 349 (20%) subjects died • 58  PD • 12  other causes • 2 intracranial hemorrhage • 5 MDS/AML • 3 pulmonary complications • 1 cardiac arrest • 1 pneumonia

  37. Safety FDA Assessment ZEVALIN™ therapy is characterized by a high incidence of cytopenias Gr. 3-4 ANC 55% Gr. 3-4 PLT 57% median duration 3-4 weeks

  38. Safety FDA Assessment Most serious AEs included • Hemorrhage  2 deaths • Myeloid malig.  5 deaths • Infections • Allergic reactions

  39. Dosimetry & Biodistribution

  40. Whole Body Biodistribution Imaging • 179 subjects assessed • Five imaging time points • Diagnostic quality imaging for multiple organs • Diagnostic quality imaging for known tumor sites

  41. Normal Organ Dosimetry • MIRDOSE 3.1 Software • Regions of Interest for Multiple Organs with Localization of Radiolabeled Antibody: Heart, Lung, Liver, Small Intestine, Spleen, Testes, Kidneys, Bone Marrow (Sacrum)

  42. Radiation Absorbed DoseNotable Organs Organ Median dose (cGy) for 32 mCi Range Spleen 1350 781-2368 Red marrow (Sacral ROI) 90 70-106 Liver 547 349-880 Testes 950 38-1184 Upper large bowel 211 122-288 Lower large bowel 368 256-467

  43. GI Toxicity (All Grades)

  44. “Worst Case” Scenarios • Adjacent normal tissues • Alteration in the biodistribution • Obstruction of clearance route - renal obstruction

  45. Dosimetry-BiodistributionFDA Assessment Normal organ dosimetry supports the use of fixed-dose of 90Y-labeled ZEVALIN™. Biodistribution is necessary for assessment of normal organ and tumor site localization

  46. Dosimetry-BiodistributionFDA Assessment • There are inadequate data to assess the safety of additive localized radiation effects from external beam radiation therapy and ZEVALIN™ therapy.

  47. Conclusions

  48. Summary Durable anti-tumor activity (ORR) was documented in both efficacy studies ZEVALIN™ therapy is associated with significant hematologic toxicity in a majority of subjects and serious morbidity in a minority of subjects.

  49. Summary • As compared to RITUXAN®, ZEVALIN™ was associated with superior ORR, similar DR and TTP. • ZEVALIN™ showed 58% ORR in RITUXAN® refractory subjects.

  50. Summary • Data are limited in non-follicular subgroups. • Data in these subgroups is limited to subjects who have not received prior RITUXAN®.

More Related